189 related articles for article (PubMed ID: 37483001)
1. Efficacy of Adjunctive Therapy with Zonisamide Versus Increased Dose of Levodopa for Motor Symptoms in Patients with Dementia with Lewy Bodies: The Randomized, Controlled, Non-Inferiority DUEL Study.
Ikeda M; Mori E; Orimo S; Yamada T; Konishi O
J Alzheimers Dis; 2023; 95(1):251-264. PubMed ID: 37483001
[TBL] [Abstract][Full Text] [Related]
2. Adjunct zonisamide to levodopa for DLB parkinsonism: A randomized double-blind phase 2 study.
Murata M; Odawara T; Hasegawa K; Iiyama S; Nakamura M; Tagawa M; Kosaka K
Neurology; 2018 Feb; 90(8):e664-e672. PubMed ID: 29367449
[TBL] [Abstract][Full Text] [Related]
3. The Application of Zonisamide to Patients Suffering from Dementia with Lewy Bodies: Emerging Clinical Data.
Tousi B; Leverenz JB
Drug Des Devel Ther; 2021; 15():1811-1817. PubMed ID: 33976533
[TBL] [Abstract][Full Text] [Related]
4. Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial.
Murata M; Odawara T; Hasegawa K; Kajiwara R; Takeuchi H; Tagawa M; Kosaka K
Parkinsonism Relat Disord; 2020 Jul; 76():91-97. PubMed ID: 31982288
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Zonisamide in Dementia with Lewy Bodies Patients with Parkinsonism: A Post Hoc Analysis of Two Randomized, Double-Blind, Placebo-Controlled Trials.
Hasegawa K; Kochi K; Maruyama H; Konishi O; Toya S; Odawara T
J Alzheimers Dis; 2021; 79(2):627-637. PubMed ID: 33337365
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-Label Extension of a Phase three Randomized Controlled Trial.
Odawara T; Hasegawa K; Kajiwara R; Takeuchi H; Tagawa M; Kosaka K; Murata M
Am J Geriatr Psychiatry; 2022 Mar; 30(3):314-328. PubMed ID: 34420834
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological management of dementia with Lewy bodies with a focus on zonisamide for treating parkinsonism.
Panza F; Lozupone M; Watling M; Imbimbo BP
Expert Opin Pharmacother; 2021 Feb; 22(3):325-337. PubMed ID: 33021110
[TBL] [Abstract][Full Text] [Related]
8. Zonisamide's Efficacy and Safety on Parkinson's Disease and Dementia with Lewy Bodies: A Meta-Analysis and Systematic Review.
Kong L; Xi J; Jiang Z; Yu X; Liu H; Wang Z
Biomed Res Int; 2022; 2022():4817488. PubMed ID: 36132085
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Management of Dementia with Lewy Bodies.
Hershey LA; Coleman-Jackson R
Drugs Aging; 2019 Apr; 36(4):309-319. PubMed ID: 30680679
[TBL] [Abstract][Full Text] [Related]
10. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Rolinski M; Fox C; Maidment I; McShane R
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
[TBL] [Abstract][Full Text] [Related]
11. Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update.
MacDonald S; Shah AS; Tousi B
Drugs Aging; 2022 Jul; 39(7):505-522. PubMed ID: 35619045
[TBL] [Abstract][Full Text] [Related]
12. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial.
Emre M; Tsolaki M; Bonuccelli U; Destée A; Tolosa E; Kutzelnigg A; Ceballos-Baumann A; Zdravkovic S; Bladström A; Jones R;
Lancet Neurol; 2010 Oct; 9(10):969-77. PubMed ID: 20729148
[TBL] [Abstract][Full Text] [Related]
13. Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs.
Marson AG; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton CO; Hughes DA; Williamson PR; Baker G; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE
Health Technol Assess; 2021 Dec; 25(75):1-134. PubMed ID: 34931602
[TBL] [Abstract][Full Text] [Related]
14. Zonisamide improves axial symptoms in dementia with Lewy bodies with parkinsonism: Post hoc analysis of clinical trials.
Tsuboi Y; Kochi K; Maruyama H; Matsumoto Y
eNeurologicalSci; 2022 Mar; 26():100384. PubMed ID: 34988303
[TBL] [Abstract][Full Text] [Related]
15. The role of levodopa in the management of dementia with Lewy bodies.
Molloy S; McKeith IG; O'Brien JT; Burn DJ
J Neurol Neurosurg Psychiatry; 2005 Sep; 76(9):1200-3. PubMed ID: 16107351
[TBL] [Abstract][Full Text] [Related]
16. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
[TBL] [Abstract][Full Text] [Related]
17. Treatment Efficacy and Acceptabilityof Pharmacotherapies for Dementia with Lewy Bodies: A Systematic Review and Network Meta-Analysis.
Chu CS; Yang FC; Tseng PT; Stubbs B; Dag A; Carvalho AF; Thompson T; Tu YK; Yeh TC; Li DJ; Tsai CK; Chen TY; Ikeda M; Liang CS; Su KP
Arch Gerontol Geriatr; 2021; 96():104474. PubMed ID: 34256210
[TBL] [Abstract][Full Text] [Related]
18. The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.
Marson A; Burnside G; Appleton R; Smith D; Leach JP; Sills G; Tudur-Smith C; Plumpton C; Hughes DA; Williamson P; Baker GA; Balabanova S; Taylor C; Brown R; Hindley D; Howell S; Maguire M; Mohanraj R; Smith PE;
Lancet; 2021 Apr; 397(10282):1363-1374. PubMed ID: 33838757
[TBL] [Abstract][Full Text] [Related]
19. Quetiapine for psychosis in Parkinson's disease versus dementia with Lewy bodies.
Fernandez HH; Trieschmann ME; Burke MA; Friedman JH
J Clin Psychiatry; 2002 Jun; 63(6):513-5. PubMed ID: 12088163
[TBL] [Abstract][Full Text] [Related]
20. Invited Perspective on the "Long-Term Efficacy and Safety of Zonisamide for Treatment of Parkinsonism in Patients With Dementia With Lewy Bodies: An Open-label Extension of a Phase 3 Randomized Controlled Trial".
Hinkle JT; Pontone GM
Am J Geriatr Psychiatry; 2022 Mar; 30(3):329-331. PubMed ID: 34429237
[No Abstract] [Full Text] [Related]
[Next] [New Search]
